Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation
Authors:
- 1 September 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (9) , 1876-1881
Abstract
Background Anti-HLA antibodies and especially donor-specific antibodies (DSA) play a significant role in graft survival after solid organ transplantation. Their impact on long-term survival in adult liver transplantation (LT) is controversial, but they may be a risk factor. The effects of DSA after pediatric LT are still unclear. Methods We performed a retrospective evaluation of DSA in sera from 43 children who had received transplants at our tertiary center. Twenty-four patients had good long-term clinical and laboratory graft function (group 1), whereas 19 LT recipients suffered from histologically confirmed and clinically relevant chronic allograft rejection (group 2); 16 of these have already undergone retransplantation due to graft dysfunction. Inclusion criteria were availability of sera before the first LT to identify preformed antibodies in case of DSA positivity after LT and long-term follow-up at our institution. Sera were analyzed for anti-HLA antibodies using Luminex single antigen beads, where a mean fluorescence intensity value of more than 1500 was considered positive. Results The prevalence of DSA was 33% for group 1 and 68% for group 2. Antibodies were predominantly HLA class II. Values of mean fluorescence intensity were comparable in both groups. Only one of the DSA+ ve patients from group 1 exhibited preformed antibodies. In conclusion, pediatric patients with chronic rejection revealed a higher rate of de novo DSA, especially of HLA-class II DSA. Further studies are necessary to confirm these data with a larger pediatric cohort.Keywords
This publication has 31 references indexed in Scilit:
- Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantationLiver Transplantation, 2013
- Antibody-mediated rejectionCurrent Opinion in Organ Transplantation, 2012
- High Mean Fluorescence Intensity Donor-Specific Anti-HLA Antibodies Associated With Chronic Rejection Postliver TransplantAmerican Journal of Transplantation, 2011
- The Significance of Donor-Specific HLA Antibodies in Rejection and Ductopenia Development in ABO Compatible Liver TransplantationAmerican Journal of Transplantation, 2011
- Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodiesLiver Transplantation, 2010
- Predictors of Survival Following Liver Transplantation in Infants: A Single-Center Analysis of More Than 200 CasesTransplantation, 2010
- Human leukocyte antigen crossmatch testing is important for liver retransplantationLiver Transplantation, 2010
- Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant StudyHuman Immunology, 2009
- Preformed Antibodies Detected by Cytotoxic Assay or Multibead Array Decrease Liver Allograft Survival: Role of Human Leukocyte Antigen CompatibilityLiver Transplantation, 2008
- Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: Experience of one centreTransplant Immunology, 2005